Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAUSE: Ustekinumab Followed by Abatacept for Psoriasis
NCT01999868Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2014
- Primary completion
- Dec 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of abatacept in plaque psoriasis, sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2014; status: completed.
02
Drugs
abatacept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01999868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999868.